Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Malaria Journal

Fig. 4

From: Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta-analysis

Fig. 4

Predicted risk of recrudescence from cause-specific Cox model and sub-distribution hazard model. The graph was generated using the regression coefficients presented in Table 5 and the estimate of baseline hazard obtained from the respective sub-distribution and cause-specific hazard model (for a 3 year old child). The cumulative baseline sub-distribution hazard on day 28 from Fine and Gray’s model was 0.006; the cumulative baseline hazard on day 28 from the cause-specific Cox model was 0.003. The vertical dotted line represents the parasitaemia of 100,000/µL for the child described in the main text. On day 28, the predicted risk of recrudescence for this patient was 16.15%, 4.76% and 4.28% using the cause-specific Cox model. The corresponding figures were 10.72%, 4.76% and 4.28% with the Fine and Gray’s sub-distribution hazard model. AL artemether–lumefantrine, ASAQ artesunate–amodiaquine, DP dihydroartemisinin–piperaquine

Back to article page